No­vo Nordisk con­tin­ues push­ing be­yond di­a­betes, net­ting PhII win for for­mer Cor­vidia kid­ney pro­gram

As No­vo Nordisk con­tin­ues look­ing at ways to ex­pand be­yond its block­buster di­a­betes busi­ness, the Dan­ish phar­ma picked up some good news from a chron­ic kid­ney dis­ease pro­gram.

No­vo’s ex­per­i­men­tal IL-6 in­hibitor zil­tivekimab passed a Phase II test Mon­day, the com­pa­ny an­nounced, re­duc­ing in­flam­ma­to­ry bio­mark­ers as­so­ci­at­ed with ath­er­o­scle­ro­sis in peo­ple with CKD. The study met its pri­ma­ry end­point with par­tic­i­pants see­ing sta­tis­ti­cal­ly sig­nif­i­cant re­duc­tions at all three dosage lev­els.

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.

SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER